MYGN (NASDAQ) - Myriad Genetics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US62855J1043
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for MYGN (NASDAQ) - Myriad Genetics Inc


Market Cap in USD 1,392m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1995-10-05


Fundamental -7.22
Dividend 0.04
Performance 5y -3.60
Rel. Performance vs Sector -3.26
Analysts 2.89
Fair Price Total Ret. 13.89
Fair Price DCF todo


Growth TTM -17.70%
CAGR 5y -18.56%
CAGR / Mean Drawdown 5y -0.38
Sharpe Ratio TTM -0.42
Alpha vs SP500 TTM -41.12
Beta vs SP500 5y weekly 1.19
CAPM 7.90%
Average Daily Range 2m 4.61%
Reversal Oscillator 32.22
Volatility GJR Garch 1y 60.06%
Price / SMA 50 -11.33%
Price / SMA 200 -20.08%
Current Volume 941.8k
Average Volume 20d 630.9k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 1.0%